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Truncation of a peptide substrate in the N-terminusand replacement of itsscissile amide bond with a non-cleavable reduced bond results in a potent 
inhibitor of HIV-l protcasc. A series of such inhibitors has been synthesized, and S2-S3’ subsites of the proteasc binding cleft mapp&. The S2 
pocket requires bulky Boc or PIV groups, large aromatic Phc residues are preferred in Pi and PI’ and Glu in P2’. The 53’ pocket prefers Phe over 
small Ala or Val. introduction of a Glu rcsiduc into the P2’ position yields a tight-binding inhibitor of HIV-l protease, Boc-Phe-[CH2-NH]-Phe- 
Glu-Phe-OMe, with a subnanomolar inhibition constant. The rclcvant peptidc derived from the same amino acid sequence binds to the proteu 
with a Ki of 1 IO nM. thus still demonstrating a good fit of lhc amino acid residues into the protcasc binding pockets and also theimportance of 
the flexibility of PI-Pl’ linkage for proper binding. A new type of peptide bond mimetic, N-hydroxylaminc -CH:-N(OH)-, has been synthesized. 
Binding of hydroxylamino inhibitor of HIV-I protease is further improved with respect o reduced-bond inhibitor. 
Inhibitor: HIV-1 protease; Enzyme subsite specificity 
1. INTRODUCTION 
The virus-encoded protease (PR) catalyzing specific 
cleavage of the polyprotein precursors of human immu- 
nodeficiency virus (HIV-l) mature proteins has become 
an obvious target for anti-viral chemotherapy [Z-4]. 
Understandably, most authors approached the design 
of an HIV-I PR-specific inhibitor by replacing a scissile 
peptide bond of a proper peptide substrate by its non- 
cleavable isostere, e.g. reduced bond [5], statine and its 
derivatives [B], hydroxyethylene [7], hydroxyethylamine 
[8,9] or difluoroketone and phosphinates [lo]. Alterna- 
tive strategies, e.g. random screening of natural 
products [l I] or the use of non-peptidic inhibitors of 
protease [ 12,131 have not yet been equally successful. 
An obvious basis for designing substrate-based inhib- 
itors has been the amino acid sequences panning the 
Abbreviutkms: DMSO, dimethylsulfoxide; Et, totalenzyme concentra- 
tion; Ki9 inhibition constant, dissociation constant ol’eneyme-inhibitor 
complex; PR, protease; HIV, human immunodcllciency virus; Nle, 
norlcucine; Nph, p-nitro-phenylalanine; MC. methyl; AC. acctyl; Boc, 
terl-buloxycarbonyl; 2, benzyloxycarbonyl protecting group; PIV. pi- 
valoyl, (r-butylcarbonyl); [C&-NH], reduced peptide bond. Tlte 
nomenclature system of Schechter and Berger [I], i.e. P2-PI *PI’-PY- 
P3’ is used to depict residues adjacent o the scissile (or reduced) bond 
situated between PI and PI’ marked by an asterisk. 
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cleavage sites in retroviral gag-pol polyprotein, mostly 
ma trix-capsid or capsid-nucleocapsid protein 
boundaries. However, the peptide substrates derived 
from these processing sites exhibit relatively high K, 
values, demonstrating thus rather poor binding to the 
protease binding cleft [3]. lnhibitors based on these sub- 
strates must comprise additional structural features 
capable of increasing the affinity of a substrate to the 
proteasc by a factor of lo5 or IO6 [lo]. Intuitively, sub- 
strates exhibiting better binding to the enzyme should 
serve as a more advantageous basis for the rational 
design of inhibitors. Recently, we presented a series of 
chromogenic peptide substrates of both HIV-i ‘and 
HIV-2 proteases with K, values in the micromolar 
range [14]. We used them for thorough mapping of 
subsite requirements of HIV-I and -2 and myelo- 
blastosis-associated virus proteases [15-l 71. In the pres- 
ent study we show that information gained from such 
substrate specificity ‘fine tuning’ may open a way to the 
design of potent, specific inhibitors based on rather 
simple chemistry. 
2. MATERIALS AND METHODS 
2. I. Hi V-1 prorrase expres5iott and prrr@curiott 
High-level expression of HIV-l PR was achieved in an adapted T7 
RNA polymcrase/promoter system [IS] and will be described in detail 
CtSCWhCiC. S?kfly, baacrittl!y c%i;XSSd .m%te %KtS purifi~ f:cXZ 
intracellular inclusion bodies isolated from isopropyllhiogalactoside- 
indu& E. co/i BL2l (DE3) cells [18] transformed with recombinanl 
Puitlisked by Elsevier ScLtrce Pubhshers 13. V. 9 
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plasmid pT7QIOHLEG (M. Andrcansky. Ph.D, Thesis, 1990; man& 
script in preparation). A 390 bp Nrlrl-EcoRl DNA fragment in the 
plasmid pT7QlOHlEG encodes mature HI’V-I protease (99 amino 
acid sequence corresponding to bru isolate); these are preceded by 
initiator mcthionine and an additional 20 upstream amino acids, The 
processing cleavage site contained in this artificial precursor is func- 
tional and allows autocatalytic processing, leading to liberation of a 
mature 99 amino acids-long protease molecule. Its carboxymterminus 
is created by a translation termination codon in the construcl. 
2.2. Syhwis ~Jinhibitors 
Inhibitors containing a reduced peptidc bond were synthesized as 
follows: corresponding tripcptides were synthesized in solution using 
r-butyloxycarbonyl protection for alpha-amino groups. Reduced 
bonds were introduced by reductive amination of appropriate N- 
protected or acylated alpha-sminoaldehydes in the presence of cyano- 
borohydride. N-protected aminoaldch$dcs were obtained by oxida- 
tion of corresponding N-protected aminoalcohols with periodinane. 
This method proved to yield optically pure protected amino aldehydes 
(details will be published clscwherc). 
The N-methyl group in compound 14 (Table II) was introduced 
using paraformaldchyde and cyanoborohydride. The N-hydroxyl- 
amine moiety in compound 15 was introduced via oxidation with t?~- 
chloro-perbenzoic acid in dichloromethane. The synthesis of hydrox- 
ycthylche isoster 12 and other synthciic details wilk bc published clse- 
where. All products were purified on rcvcrscd phase HPLC (C-18 
VYDAC column with 0.05% aqueous TFA-methanol as the mobile 
phase, UV detection at 220 nm) and characterized by FAB mass 
spectromctry. quantitativeamino acid analysis and elemental analysis. 
All the inhibitors were readily soluble in DMSO. Typically, 2 mM 
stock solutions were prepared and used for inhibition measurements. 
2.3. hfdbihn srrrciies 
Inhibition constants of the inhibitors were determined using a spcc- 
trophotometcr assay with chromogenic peptide substrate Lys-Alaa 
ArpVal-Nle-Nph-Glu-Ala.NleNH: [14]. Typically, 5 pmole of HIV- 
I PR was added to I ml of a 10 PM solution of the substrate and 
various concentration of an inhibitor in 0.1 M sodium acetate bufI’er, 
pH 4.7. with 0.3 M NaCl and 4 mM EDTA. The initial velocities (the 
depletion of the substrate less than 10%) were measured on a UV-VIS 
spectrophotometcr Aminco DW 2000 as a decrease of absorbance at 
305 nm [14,17] at 37’C and fitted to the Dixon analysis [l9], i.e. l/v 
vs., theconcentration of I. The K, values lower than 5 nM were assessed 
using the equation [20]: 
[El= ([E],+[I],+Kia)l2 + sqrt(sqrt([E,]+[l],tK,a) - 4[E],*[P]J2 
where ihe apparent equilibrium dissociation constant Kia should be 
corrected into the true K, as Ki= K,aI(l+[SyK,). 
The HIV-1 PR concentration was evaluated by titrating with subna- 
nomolar concentrations of inhibitor, quinoline-2-carbonyl-Asn-Phc- 
psi (CHOH-CH,N)~ecahydro~isoquinoline-carbonyI-NH-r-butyl[8], 
and independently with compound I9 or 20 (Table 111). The titration 
of the HIV-I PR with inhibitor 19 (shown in Fig. I) was performed 
under the following conditions: l-10 ~1 of 0.6pM inhibitor BocmPhe 
[CHI-NH] Phe-GlumPhe-OMe (compound 19) in DMSO were added 
to a cuvette with 3.3 nM solution of HIV-I PR in 100 ,ul of 0.1 M 
acetale buffer, pH 4.7, with 0.3 M NaCl and 4 mM EDTA. The 
reaction was started by addition of 3 ~1 5 mM solution on chromo- 
genic substrate Lys-Ala-Arg-Val-Nle-Nph-Glu-Ala-Nle-NH1 and fol- 
lowed on a spectrophotomctcr Aminco DW 2000 at 305 nm. Remain- 
ing enzyme activity was plotted against concentration of the inhibitor. 
The cleavage of the pcptide 21 wns performbxl under similar condi- 
tions as dcscribcd abo\lc. After 2 h incubation the reaction mixture was 
quenched by the addition of 20% TFA to a final concentration of 5% 
and applied on reversed phase HPLC. The peaks corresponding to the 
hydrolysis products were collected and the actual cleavage site deter- 
mined by N-terminal sequencing and amino acid analysis. 
10 
3. RESULTS AND DISCUSSION 
In th& paper we have compared the series of inhib- 
itors which map requirements in 52, Sl and Sl’ enzyme 
binding subsites. We designed a series of N-protected, 
tctrapeptides, based on an amino acid sequence of in- 
hibitor 1 (Table I), which have a reduced peptide bond 
proximal to the N-terminus. Structure-activity data ob- 
tained on this set of inhibifors based on simple chemis- 
try could be used for the design of potentially even more 
active compounds, e.g. hydroxyethylene- or hydrox- 
yethyl- amino-isosteres. 
The reduced bond is situated between two phenyla- 
lanine residues that we found to be favorable in Pl and 
Pl’ positions [16,22]. This led to an inhibitor with a 
remarkably lower Ki value than found for any inhibitor 
based on the reduced bond analogue. Table 1 sum- 
marizes the influence of the nature of the protecting 
group on binding of an inhibitor to the S2 protease 
subsite. The bulky tert-butyl-oxy-carbonyl group fits to 
the S2 subsite better than the large hydrophobic benzyl- 
oxy-carbonyl or small acetyl group. Charged, un- 
protected N-terminus (compound S), prolongation or 
extension of the amino acid chain at the N-terminus 
(compounds 6 and 7) sharply decreases binding and 
shifts the Ki value to the higher range. A representative 
of a conventional inhibitor derived from the sequence 
spanning the matrix-nucleocapsid (MA-CA) boundary 
of HLV-1 polyprotein is compound 8 (Table I). Micro- 
molar ICsO or Ki values were reported also for other 
reduced-bond inhibitors derived from different process- 
ing sites in HIV-l polyprotein [6,24]. The weaker bind- 
ing indicates that the extended peptide structure of the 
inhibitor on the non-prime side orients the inhibitor 
differently and to some extent disturbs optimal binding 
of the rest of the inhibitor. 
Inhibitors shown in Table II map the requirements 
for SI-Sl’ subsites neighboring the reduced peptide 
bond. All the replacements (compounds 9, 10, 11, 13, 
14) lead to lower inhibition activity of resulting inhib- 
itors which correlates with similar findings of increasing 
of K,,, values of HIV-1 PR peptide ,substrates when sim- 
Table I 
Reduced-bond inhibitors of HIV-I protease with variations in the 
N-terminus 
- 
Number Sequcncc KI (nM) 
PI Pl’ P2’ P3’ 
: 
Boc-Phe [CH,-NH] Phe-Ile-Phe-OMe 23 
Piv-Phe [CH,-NH] Phe-Ile-Phe-OMc 36 
3 2.Phe [CHI-NH] Phe.Ile-Phe-OMe 200 
4 Ac-Phe [CH>-NH] Phc-Ilc-Phe-OMc 800 
5 Phe [CH:-NH] Phc-Ile-Phe-OMe 11,000 
B Val.Phe ICH,-NH] Phe-Ile-Phc-OMc 2,700 
Boc-Val-Phe [CH,-NH] Phe-Ile-Phc.OMe 
i Scr-GlnAsn-Tyr [CHz-NH] 
750 
Pro-Ilc-Val-Gin 9,000 
All details are given in Materials and Methods, 
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Fig. I. Active-site titration of HIV-1 PR by inhib’itor 19. Boc-Phc- 
[CH,-NH]-Phc-Glu-Phc-OMc. For conditions SW Materials and 
Methods. 
‘ilar replacements in substrate annlogues (Phe-Nle, Phe- 
Gly) were introduced [14,16]. The SO-fold drop in Kj 
from compound I1 to 12 documents particularly the 
important role of the nature of the PI-PI’ peptide bond 
mimetic and superiority of hydroxyisostere over the re- 
duced bond in binding to protease active cylinder. 
Hydroxyisostere 12 clearly compensates for the disad- 
vantage of the absence of the side chain in PI’ and 
restores essentially the inhibition potency of a prototype 
compound 1. Insertion of N-methylated peptide bond 
(compound 14) on the other hand, results in a IO-fold 
increase in Ki. The introduction of hydroxy-ethylidene 
isostere into compound 13 leads to fixed non-flexible 
conformation and decrease of inhibitory activity. 
N-Hydroxylamine isostere (Scheme I), inhibitor 1 S 
(Table II), is synthesized via oxidation of the reduced 
bond inhibitor 1. This peptide bond mimetic improves 
binding by a factor of 50, similar to the improvement 
observed upon insertion of hydroxyethylene isostere in- 
stead of a reduced peptide bond (compounds 11 and 
Table II 
Reduced-bond inhibitorsof HIV-I protcarc with variation in Pi’-PI’ 
posilions 
Number Sequence Ki (nM) 
I 
9 
10 
II 
12 
13 
14 
15 
P1 
Boc-Phc 
Boc-Nle 
Boc-Nle 
Boc-Phe 
Boc-Phc 
Boc-Phe 
Eoc-Phe 
Boc-Phe 
[Cl+NH] 
[CH*--N H] 
[CHz-NH] 
[CHz-NH] 
[CH(OH}-LHI] 
[CH(OH~-CH=] 
WWW~)l 
KHJWW 
Pl’ P2’ P3’ 
Phc-llc-Phc-OMe 23 
Phc-lie-Phc-OMc 110 
Nlc-Ilc-Phc-OMe 450 
Gly-Tic-Phe-OMc 1,650 
Cily-Ilc-Phe-OMe 
Gly-Ile-Phc-OMe 5,;: 
Phc-Ile-Phe-OMe 390 
Phe-lie-Phc-OMe OS 
12). This suggests that the hydroxyl group of hydroxyl- 
amine I5 binds between the two catalytical aspartates 
and excludes the water molecule from the protease ac- 
tive site [23]. 
Inhibitors shown in Table III were designed in order 
to investigate the nature of the residue occupying the P2’ 
and P3’ positions. The P2’ position was found to be 
particularly critical. Leu or Val (compound 16 and 17) 
had a minor effect on Kiq in good agreement with data 
published on synthetic peptide substrates [22]. Ala in the 
same position (compound 18) increases Ki of the result- 
ing inhibitor by an order of magnitude. 
Previously, we have reported the design of a sensitive 
chromogenic substrate of HIV-I PR [14] exhibiting a 
20.times lower K, value than other substrates described 
R H = INHlBlfCR 1 
R = CH3 INHIBITOR 14 
R = OH INHIBITOR 15 
CONH, 
INHIBITOR 12 
All the details arc given in Materials nnd Methods. INHEIITOR 13 
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so far. The particular feature of that substrate was a 
glutamic acid residue in the P2’ position. Insertion of 
the same residue into the P2’ position of a reduced-bond 
inhibitor (compound 19, Table Ill) dramatically dc- 
creased the Kj value, thus showing the ideal fit of the 
peptide chain into the active site binding pockets. Com- 
pound 19 is a tight-binding competitive inhibitor of 
HIV-1 protease and is suitable for its active site titration 
(Fig. 1). Removal of the negative charge by Glu-Gln 
replacement (compound 23) results in a 20-fold decrease 
in binding which is then further lowered by a change to 
the homological Asn residue (compound 24). A remark- 
able drop in the inhibitory activity can be seen in the 
case of Glu-Asp replacement when the negative charge 
of the P2’ side chain is preserved (compound 22). The 
increase of Ki by four orders of magnitude achieved by 
the removal of a single methylene in the side chain of 
an amino acid in the P2’ position shows high specificity 
of the interaction of Glu in P2’. Compounds 25 and 26 
are analogues of the parent compound 1 having the Phe 
in P3’ replaced by Ala and Val, respectively. Both re- 
placements lead to higher Ki values. 
cleavage between both Phe residues. The correct cleav- 
age site is an indirect proof of our assumption that the 
reduced bond or hydroxylamine isosteres of the ‘trun- 
cated’ inhibitors are located between the active site 
aspartate. 
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